Method of identifying a modulator of a LTβR complex signaling pathway
The invention relates to compositions and methods comprising lymphotoxin-beta receptor (LTβR) modulators, which activate or inhibit LTβR signaling. LTβR modulators are useful for treating lymphocyte mediated immunological diseases and cancer, and more particularly, for regulating mitochondrial-mediated apoptosis. This invention relates to soluble forms of the LTβR complex proteins that act as LTβR activating or inhibiting agents. This invention also relates to the use of soluble molecules, directed against either the LTβR, its ligands, LIGHT and LTβ1α2, or its intracellular binding partners, that function to regulate LTβR signaling. A novel screening method for selecting soluble receptors, antibodies and other agents that modulate LTβR signaling is provided.
1. A method of identifying a modulator of a lymphotoxin beta receptor (LTβR) complex signaling pathway, the method comprising
contacting a cell expressing an LTβR polypeptide with a test agent;
determining whether the test agent modulates activity or expression of a Smac polypeptide in said cell; and
further determining whether a test agent that modulates activity or expression of a Smac polypeptide directly interferes with LTβR-ligand binding,
wherein interference with LTβR-ligand binding identifies said test agent as a modulator of a lymphotoxin beta receptor (LTβR) complex signaling pathway.
2. The method of claim 1 , further comprising determining whether the test agent modulates mitochondrial-mediated apoptosis in said cell.
3. The method of claim 1 , wherein said LTβR ligand is a LIGHT polypeptide complex.
4. The method of claim 1 , wherein said LTβR ligand is a Ltα1f32 polypeptide complex.
5. The method of claim 1 , wherein said LTβR complex comprises LTβR, TRAF3, TRAF2, cIAP1, and Smac polypeptides.
6. The method of claim 1 , wherein said modulation is inhibition of the LTβR complex signaling pathway.
7. The method of claim 1 , wherein said modulation is enhancement of the LTβR complex signaling pathway.
8. A method of identifying a modulator of a lymphotoxin beta receptor (LTβR) complex signaling pathway, the method comprising
contacting a cell expressing an LTβR with a test agent;
determining whether the test agent modulates activity or expression of a cIAP1 polypeptide in said cell; and
further determining whether a test agent that modulates activity or expression of a cIAP1 polypeptide directly interferes with LTβR-ligand binding,
wherein interference with LTβR-ligand binding identifies said test agent as a modulator of a lymphotoxin beta receptor (LTβR) complex signaling pathway.
9. The method of claim 8 , further comprising determining whether the test agent modulates mitochondrial-mediated apoptosis in said cell.
10. The method of claim 8 wherein said LTβR ligand is a LIGHT polypeptide complex.
11. The method of claim 8 wherein said LTβR ligand is a Ltα1β2 polypeptide complex.
12. The method of claim 8 , wherein said LTβR complex comprises LTβR, TRAF3, TRAF2, cIAP1, and Smac polypeptides.
13. The method of claim 8 , wherein said modulation is inhibition of the LTβR complex signaling pathway.
14. The method of claim 8 , wherein said modulation is enhancement of the LTβR complex signaling pathway.
15. A method of identifying a modulator of a lymphotoxin beta receptor (LTβR) complex signaling pathway, the method comprising
contacting a cell expressing an LTβR with a test agent;
determining whether the test agent modulates activity or expression of a TRAF2 polypeptide in said cell; and
further determining whether a test agent that modulates activity or expression of a TRAF2 polypeptide directly interferes with LTβR-ligand binding,
wherein interference with LTβR-ligand binding identifies said test agent as a modulator of a lymphotoxin beta receptor (LTβR) complex signaling pathway.
16. The method of claim 15 , further comprising determining whether the test agent modulates mitochondrial-mediated apoptosis in said cell.
17. The method of claim 15 , wherein said LTβR ligand is a LIGHT polypeptide complex.
18. The method of claim 15 , wherein said LTβR ligand is a Ltα1β2 polypeptide complex.
19. The method of claim 15 , wherein said LTβR complex comprises LTβR, TRAF3, TRAF2, cIAP1, and Smac polypeptides.
20. The method of claim 15 , wherein said modulation is inhibition of the LTβR complex signaling pathway.
21. A method of identifying a modulator of a lymphotoxin beta receptor (LTβR) complex signaling pathway, the method comprising
contacting a cell expressing an LTβR polypeptide with a test agent;
determining whether the test agent modulates activity or expression of an ERH polypeptide in said cell; and
further determining whether a test agent that modulates activity or expression of an ERH polypeptide modulates LTβR-ligand binding,
wherein interference with LTβR-ligand binding identifies said test agent as a modulator a modulator of a lymphotoxin beta receptor (LTβR) complex signaling pathway.
22. The method of claim 21 , further comprising determining whether the test agent modulates mitochondrial-mediated apoptosis in said cell.
23. The method of claim 21 , wherein said LTβR ligand is a LIGHT polypeptide complex.
24. The method of claim 21 , wherein said LTβR ligand is a Ltα1β2 polypeptide complex.
25. The method of claim 21 , wherein said LTβR complex comprises LTβR, TRAF3, TRAF2, cIAP1, and Smac polypeptides.
26. The method of claim 21 , wherein said modulation is inhibition of the LTβR complex signaling pathway.
27. The method of claim 21 , wherein said modulation is enhancement of the LTβR complex signaling pathway.